RPT193
DrugAntagonist of the CCR4 chemokine receptor
NCT Number: NCT04271514
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
PRA, Groningen, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Selected Inclusion Criteria:
Parts A & B (COMPLETED ENROLLMENT):
Part C (COMPLETED ENROLLMENT):
Selected Exclusion Criteria:
Parts A & B (COMPLETED ENROLLMENT):
Part C (COMPLETED ENROLLMENT):
Antagonist of the CCR4 chemokine receptor
Matching placebo
Time frame: up to Day 16 (Part A: SAD); up to Day 22 (Part B: MAD); up to Day 43 (Part C)
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment
RAPT Therapeutics, Inc.
Industry
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06687512
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ahmedabad, Gujarat, India
View Trial DetailsNCT05613062
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hong Kong
View Trial DetailsNCT05633355
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Phoenix, Arizona, United States
View Trial DetailsNCT05899816
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Scottsdale, Arizona, United States
View Trial Details